Table 3 Acute toxicities after concurrent chemoradiotherapy for bladder preservation
From: Upper Egypt experience in bladder preservation using concurrent chemoradiotherapy
Acute toxicity* | I | II | III | |||
|---|---|---|---|---|---|---|
Group A | Group B | Group A | Group B | Group A | Group B | |
10% | 26.7% | 16.6% | 13.2% | 0% | 3.3% | |
20% | 9.9% | 6.6% | 3.3% | 3.3% | 3.3% | |
3.3% | 16.5% | 3.3% | 6.6% | 0% | 0% | |
40% | 40% | 6.6% | 23.3% | 0% | 3.3% | |
43.3% | 46.7% | 13.3% | 46.7% | 0% | 6.6% | |
60% | 23.3% | 10% | 6.6% | 0% | 0% | |
33.3% | 36.7% | 60% | 53.3% | 6.6% | 6.6% | |
12% | 43.3% | 20% | 36.7% | 3.3% | 16.5% | |
26.6% | 6.6% | 6.6% | 3.3% | 0% | 3.3% | |
0% | 0% | 0% | 0% | 0% | 0% | |
0% | 13.2% | 0% | 0% | 0% | 0% | |
23.3% | 76.7% | 0% | 0% | 0% | 0% |